USP10 promotes glioma stem cell maintenance and glioblastoma growth by antagonizing DTX3L-mediated SATB2 ubiquitination
pharmacological inhibition of USP10 by Wu-5 effectively suppresses tumor growth
Special AT‑rich sequence‑binding protein 2 (SATB2) is a nuclear matrix‑associated protein with a pivotal role in glioblastoma (GBM) progression. Here we identify the ubiquitin specific peptidase 10 (USP10) as a deubiquitinase and the deltex E3 ubiquitin ligase 3 L (DTX3L) as a ubiquitin ligase of SATB2 in glioma stem cells (GSCs). USP10 and DTX3L regulate SATB2 ubiquitination at the K266 residue through mutually exclusive interactions and opposing activities. USP10, enriched in GSCs, is induced by transcription factor YY2. Knockdown of USP10 or overexpression of DTX3L markedly down‑regulates SATB2, resulting in the inhibition of GSC self‑renewal and GBM growth, which can be rescued by the overexpression of SATB2. Importantly, pharmacological inhibition of USP10 by Wu‑5 effectively suppresses tumor growth. These findings highlight the antagonistic roles of USP10 and DTX3L in the regulation of GBM malignancy and propose USP10 as a potential therapeutic target.
The study demonstrates that USP10 stabilizes the oncogenic protein SATB2 in glioblastoma stem cells, promoting tumor growth, and that its inhibition by the small‑molecule inhibitor Wu‑5 blocks this oncogenic pathway, offering a promising therapeutic strategy for glioblastoma.
Bizonyítékszint: Számítógépes vagy elméleti. Modellből vagy adatbányászatból származó jel.
Kapcsolódó jelek
- Glioma
- Glioblastoma Clinical Trials for New Treatments
- Clinical trial links oncolytic immunoactivation to survival in glioblastoma
- Treating the invisible target: treatment planning targeting the microscopic tumor spread in gliomas
- EGFR inhibition down-regulates MGMT and enhances responsiveness to temozolomide in glioblastoma